脳科学辞典

「テスト」の版間の差分

ページ

テスト (ソースを閲覧)

2021年2月17日 (水) 21:27時点における版

4,587 バイト追加 、 2021年2月17日 (水)
細
編集の要約なし
細編集の要約なし
細編集の要約なし
 
(2人の利用者による、間の80版が非表示)
1行目: 1行目:
{|style="text-align: left;"
{| class="wikitable"
|+style="background-color: lightskyblue;"|
!化合物!!ClinicalTrials.gov Identifier !! 年 !! 国 !! 対象疾患 !! Phase !! 結果
'''[[チロシンキナーゼ]]'''
|-
|-
!colspan="3" align="center" style="background-color:lightskyblue;"|[[受容体型チロシンキナーゼ]]
| Taltirelin Hydrate || [https://www.clinicaltrials.gov/ct2/show/NCT04107740 NCT04107740] || 2019- || 韓国 || SCD全般 || 4 || 現在進行中
|-
|-
!rowspan="7" style="background-color:lightskyblue;"| [[成長因子受容体]]
| KPS-0373(Rovatirelin) || [https://www.clinicaltrials.gov/ct2/show/NCT01970098 NCT01970098] || 2013-2015 || 日本 || 軽度～中等度のSCD || 3 || [https://jnnp.bmj.com/content/91/3/254 部分的に有効]
|style="background-color:lightskyblue;"|[[ErbB|上皮成長因子受容体ファミリー]]||[[EGFR]], [[HER2/neu|ERBB2]], [[ERBB3]], [[ERBB4]]
|-
|-
|style="background-color:lightskyblue;"|[[インスリン受容体]]ファミリー||[[IGF1R]], [[INSR]], [[INSRR]]
| Riluzole || [https://www.clinicaltrials.gov/ct2/show/NCT03347344?cond=Spinocerebellar+Degeneration&draw=3&rank=11 NCT03347344] || 2018-2019 || フランス || SCA2 || 3 || 不明
|-
|-
|style="background-color:lightskyblue;"|[[PDGF受容体ファミリー]]|| [[CSF1R]], [[FLT3]], [[KIT]], [[PDGFR]] ([[PDGFRA]], [[PDGFRB]])
| Transcranial Magnetic Stimulation || [https://www.clinicaltrials.gov/ct2/show/NCT03347344 NCT01975909] || 2013-2016 || 米国 || genetically-confirmed SCA || Not Applicable || 有効性なし
|-
|-
|style="background-color:lightskyblue;"|[[FGF受容体]]ファミリー
| Lithium Carbonate || [https://www.clinicaltrials.gov/ct2/show/NCT00683943 NCT00683943] || 2008－2010 || 米国 || SCA1 || 1 ||
||[[FGFR1]], [[FGFR2]], [[FGFR3]], [[FGFR4]]
|-
|-
|style="background-color:lightskyblue;"| [[VEGF受容体s]]ファミリー
| Intravenous Immune Globulin || [https://www.clinicaltrials.gov/ct2/show/NCT02287064 NCT02287064] || 2015－2016 || 米国 || SCA types 1, 2, 3, 6, 10, or 11 || 1 || まだ発表なし
|| [[FLT1|VEGFR1]], [[VEGFR2]], [[VEGFR3]], [[VEGFR4]]
|-
|-
|style="background-color:lightskyblue;"| [[C-Met|HGF受容体]]ファミリー
| Oral Trehalose || [https://www.clinicaltrials.gov/ct2/show/NCT04399265 NCT04399265] || 2020ー- || マレーシア || Genetically confirmed SCA 3 || Not Applicable || 進行中
|[[MET]], [[RON]]
|-
|-
|style="background-color:lightskyblue;"| [[Trk受容体]]ファミリー
| Varenicline (Chantix®) || [https://www.clinicaltrials.gov/ct2/show/NCT00992771 NCT00992771] || 2009－2012 || 米国 || SCA3 || 2 || [https://n.neurology.org/content/78/8/545.long 有効]
|[[NTRK1]], [[NTRK2]], [[NTRK3]]
|-
|-
! align="left" colspan="2" style="background-color:lightskyblue;"|[[Eph受容体]]ファミリー
| Umbilical Cord Mesenchymal Stem Cells || [https://www.clinicaltrials.gov/ct2/show/NCT03378414 NCT03378414] || 2017－ || 中国 || SCA1,2,4,6 || 2 || 詳細不明
||[[EPHA1]], [[EPHA2]], [[EEPHA3]], [[EPHA4]], [[EPHA5]], [[EPHA6]], [[EPHA7]], [[EPHA8]], [[EPHB1]], [[EPHB2]], [[EPHB3]], [[EPHB4]], [[EPHB5]], [[EPHB6]], [[EPHX]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[Leukocyte受容体 チロシンキナーゼ|LTK受容体]]ファミリー
| Troriluzole || [https://www.clinicaltrials.gov/ct2/show/NCT02960893 NCT03701399] || 2018－ || 米国 || SCA1,2,3,6,7,8,10 || 2，3 || 進行中
|[[Leukocyte受容体 チロシンキナーゼ|LTK]], [[Anaplastic lymphoma kinase|ALK]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[Angiopoietin受容体|TIE受容体]]ファミリー
| Sodium Phenylbutyrate || [https://www.clinicaltrials.gov/ct2/show/NCT01096095 NCT01096095] || 2010－2012 || ブラジル || SCA3 || 2 || 中止
|[[TIE]], [[TEK]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[受容体チロシンキナーゼ様オーファン受容体|ROR受容体]]ファミリー
| Dalfampridine || [https://www.clinicaltrials.gov/ct2/show/NCT01811706 NCT01811706] || 2013－2015 || 米国 || SCA1,2,3,6 || Not Applicable || 有効性なし
|[[ROR1]], [[ROR2]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"| [[DDR1|DDR受容体]]ファミリー
| CAD-1883 || [https://www.clinicaltrials.gov/ct2/show/NCT04301284 NCT04301284] || 2020－ || 米国 || SCA1,2,3,6,7,10,17 || 2 || 延期(COVID-19のため
|[[DDR1]], [[DDR2]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"| [[PTK7|PTK7受容体]]ファミリー
| Docosahexaenoic Acid (DHA) || [https://www.clinicaltrials.gov/ct2/show/NCT03109626 NCT03109626] || 2015－2018 || イタリア || SCA38 || Not Applicable || [https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25059 有効]
|[[PTK7]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[related to受容体 チロシンキナーゼ|RYK受容体]]ファミリー
| Stemchymal® || [https://www.clinicaltrials.gov/ct2/show/NCT02540655 NCT02540655] || 2015－ || 台湾 || SCA2,3 || 2 || 不明
|[[RYK]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[MuSK protein|MuSK受容体]]ファミリー
| Intravenous Cabaletta || [https://www.clinicaltrials.gov/ct2/show/NCT02147886 NCT02147886] || 2014-2016 || イスラエル || SCA3 || 2 || 結果？
|[[MUSK]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[ROS1 (gene)|ROS受容体]]ファミリー
| Coenzyme Q10 || [https://www.clinicaltrials.gov/ct2/show/NCT00957216 NCT00957216] || 2009－2018 || 米国 || 弧発性SCD || 1 || 結果？
|[[ROS1]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[AATK|AATYK受容体]]ファミリー
| BHV-4157 || [https://clinicaltrials.gov/ct2/show/NCT03408080 NCT03408080] || 2018－ || 米国 || SCA1,2,3,6 || 3 || エントリー中止中
|[[AATYK]], [[AATYK2]], [[AATYK3]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"| [[AXL受容体 チロシンキナーゼ|AXL受容体]]ファミリー
| Vatiquinone || [https://www.clinicaltrials.gov/ct2/show/NCT04577352 NCT04577352] || 2020－ || 米国 || Friedreich Ataxia || 2，3 || 開始前
| [[AXL]], [[MER]], [[TYRO3]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[RET proto-oncogene|RET受容体]]ファミリー
| CTI-1601 || [https://www.clinicaltrials.gov/ct2/show/NCT04519567 NCT04519567] || 2020－ || 米国 || Friedreich Ataxia || 1 || 開始前
|[[RET]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|未分類
| Etravirine || [https://clinicaltrials.gov/ct2/show/NCT04273165 NCT04273165] || 2020－ || イタリア || Friedreich Ataxia || 2 || 開始前
|[[STYK1]]
|-
|-
!colspan="3" align="center" style="background-color:lightskyblue;" |[[非受容体型チロシンキナーゼ]]
| RT001 || [https://www.clinicaltrials.gov/ct2/show/NCT04102501 NCT04102501] || 2019- || 米国 || Friedreich Ataxia || 3 || 進行中
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[Abl gene|ABL]]ファミリー
| Resveratrol || [https://clinicaltrials.gov/ct2/show/NCT03933163 NCT03933163] || 2019- || 米国 || Friedreich Ataxia || 2 || 進行中
| [[ABL1]], [[ARG]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[TNK2|ACK]]ファミリー
| MIN-102 || [https://clinicaltrials.gov/ct2/show/NCT03917225 NCT03917225] || 2019－ || EU || Friedreich Ataxia || 2 || リクルート終了
|[[ACK1]], [[TNK1]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[CSK]]ファミリー
| gamma interferon || [https://clinicaltrials.gov/ct2/show/NCT03888664 NCT03888664]<br>[https://clinicaltrials.gov/ct2/show/NCT02797080 NCT02797080]<br>[https://clinicaltrials.gov/ct2/show/NCT02593773 NCT02593773]<br>[https://www.clinicaltrials.gov/ct2/show/NCT01965327 NCT01965327]||  ||  || Friedreich Ataxia || 2、3 ||
| [[CSK]], [[MATK]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"| [[FAK]]ファミリー
| Nicotinamide || [https://clinicaltrials.gov/ct2/show/NCT03761511 NCT03761511] || 2018- || EU || Friedreich Ataxia || 2 || 進行中
| [[FAK]], [[PYK2]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"| [[Feline sarcoma oncogene|FES]]ファミリー
| TAK-831 || [https://www.clinicaltrials.gov/ct2/show/NCT03214588 NCT03214588] || 2017-2019 || 米国 || Friedreich Ataxia || 2 || 有効性なし
|[[FES]], [[FER]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"| [[Fyn-related kinase|FRK]]ファミリー
| Rosuvastatin || [https://www.clinicaltrials.gov/ct2/show/NCT02705547 NCT02705547] || 2016-2018 || 米国 || Friedreich Ataxia || 1 || リクルート終了
| [[FRK]], [[BRK]], [[SRMS]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[Janus kinase|JAK]]ファミリー
| (+)-Epicatechin || [https://clinicaltrials.gov/ct2/show/NCT02660112 NCT02660112] || 2016-2019 || 米国 || Friedreich Ataxia || 2 || 有効性なし
|[[JAK1]], [[JAK2]], [[JAK3]], [[TYK2]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[SRC-A]]ファミリー
| Methylprednisolone || [https://www.clinicaltrials.gov/ct2/show/NCT02424435 NCT02424435] || 2015-2020 || 米国 || Friedreich Ataxia || 1 || リクルート終了
|[[SRC]], [[FGR]], [[FYN]], [[YES1]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[SRC-B]]ファミリー
| EPI-743(alpha-tocotrienol quinone) || [https://clinicaltrials.gov/ct2/show/NCT01962363 NCT01962363] || 2013-2016 || 米国 || Friedreich's Ataxia with Point Mutations || 2 || [https://n.neurology.org/content/86/16_Supplement/P5.388 効果あり]
|[[BLK]], [[HCK]], [[LCK]], [[LYN]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[TEC (gene)|TEC]]ファミリー
| Omaveloxolone || [https://clinicaltrials.gov/ct2/show/NCT02255435 NCT02255435] || 2014- || 米国 || Friedreich Ataxia || 2 || リクルート停止
|[[TEC]], [[BMX]], [[BTK]], [[ITK]], [[TXK]]
|-
|-
!colspan="2" style="background-color:lightskyblue;"|[[Syk|SYK]]ファミリー
| Acetyl-L-Carnitine || [https://www.clinicaltrials.gov/ct2/show/NCT01921868 NCT01921868] || 2013-2017 || 米国 || Friedreich Ataxia || Not Applicable || 結果未報告
|[[SYK]], [[ZAP70]]
|-
| VP 20629 || [https://clinicaltrials.gov/ct2/show/NCT01898884 NCT01898884] || 2013-2016 || 米国 || Friedreich Ataxia || 1 || リクルート終了
|-
| EPI-743 || [https://clinicaltrials.gov/ct2/show/NCT01728064 NCT01728064] || 2012-2015 || 米国 || Friedreich Ataxia || 2 || 有効性なし
|-
| Bupropion and Citalopram || [https://clinicaltrials.gov/ct2/show/NCT01716221 NCT01716221] || 2012-2016 || 米国 || Friedreich Ataxia || 4 || 終了
|-
| Resveratrol || [https://clinicaltrials.gov/ct2/show/NCT01339884 NCT01339884] || 2011-2014 || オーストラリア || Friedreich Ataxia || 1,2 || 終了
|-
| Idebenone || [https://clinicaltrials.gov/ct2/show/NCT01303406 NCT01303406] || 2011-2016 || EU || Friedreich Ataxia || 3 || 有効性なし
|-
| A0001(alpha-tocopherolquinone) || [https://clinicaltrials.gov/ct2/show/NCT01035671 NCT01035671] || 2009-2011 || 米国 || Friedreich Ataxia || 2 || [https://onlinelibrary.wiley.com/doi/full/10.1002/mds.25058 容量依存性にFRDA評価スケール改善]
|-
| Erythropoietin || [https://clinicaltrials.gov/ct2/show/NCT01016366 NCT01016366] || 2009-2016 || EU || Friedreich Ataxia || 2 || 有効性なし
|-
| idebenone || [https://clinicaltrials.gov/ct2/show/NCT00993967 NCT00993967] || 2009-2016 || EU || Friedreich Ataxia || 3 || 認容性を副作用の確認
|-
| deferiprone || [https://clinicaltrials.gov/ct2/show/NCT00530127 NCT00530127] || 2007-2009 || EU || Friedreich Ataxia || 1,2 || [https://onlinelibrary.wiley.com/doi/full/10.1002/ana.24248 非重症例で進行抑制の可能性(+)]
|-
| EGb 761 || [https://clinicaltrials.gov/ct2/show/NCT00824512 NCT00824512] || 209-2013 || フランス || Friedreich Ataxia || 2 || 有効性なし
|-
| pioglitazone || [https://clinicaltrials.gov/ct2/show/NCT00811681 NCT00811681] || 2008-2013 || フランス || Friedreich Ataxia || 3 || 終了
|-
| varenicline || [https://www.clinicaltrials.gov/ct2/show/NCT00803868 NCT00803868] || 2008-2010 || 米国 || Friedreich Ataxia || 2，3 || 途中で中止
|-
| Triheptanoin || [https://clinicaltrials.gov/ct2/show/NCT04513002 NCT04513002] || 2020- || オーストラリア || Ataxia Telangiectasia || 2 || リクルート開始前
|-
| vitamin B3 || [https://clinicaltrials.gov/ct2/show/NCT03962114 NCT03962114] || 2019- || オランダ || Ataxia Telangiectasia || 2 || リクルート中
|-
| N-Acetyl-L-Leucine || [https://clinicaltrials.gov/ct2/show/NCT03759678 NCT03759678] || 2018- || 米，英，独 || Ataxia Telangiectasia || 2 || リクルート中
|-
| Metformin，Pioglitazone || [https://clinicaltrials.gov/ct2/show/NCT02733679 NCT02733679] || 2016-2019 || 英国 || Ataxia Telangiectasia || 4 || 終了
|-
| Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate || [https://clinicaltrials.gov/ct2/show/NCT01052623 NCT01052623] || 2010-2011 || ドイツ || Ataxia Telangiectasia || 4 || 結果？
|-
| amantadine sulphate || [https://clinicaltrials.gov/ct2/show/NCT00950196 NCT00950196] || 2009-2011 || イスラエル || Ataxia Telangiectasia || 4 || [https://journals.sagepub.com/doi/10.1177/0883073812441999 運動症状を改善]
|-
| Baclofen || [https://clinicaltrials.gov/ct2/show/NCT00640003 NCT00640003] || 2008-2011 || 米国 || Ataxia Telangiectasia || 1 || 結果？
|}
|}
「https://bsd.neuroinf.jp/wiki/特別:携帯機器差分/19662...45878」から取得